Adalimumab vs. Conventional Immunosuppression for Corticosteroid-sparing for Uveitis (ADVISE) Trial
The ADalimumab Vs. conventional ImmunoSupprEssion for uveitis (ADVISE) Trial is a randomized, comparative effectiveness trial comparing adalimumab to conventional agent immunosuppression for patients with non-infectious, intermediate, posterior, and panuveitides. Scheie Eye Institute, the Department of Ophthalmology, University of Pennsylvania will not enroll any patients under 18 years of age.
- Study Identifier: 832873
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required